

## Article

# A Matched-Pair Analysis after Robotic and Retropubic Radical Prostatectomy: A New Definition of Continence and the Impact of Different Surgical Techniques

Nicola d'Altilia <sup>1</sup>, Vito Mancini <sup>1</sup>, Ugo Giovanni Falagario <sup>1</sup>, Leonardo Martino <sup>1</sup>, Michele Di Nauta <sup>1</sup>, Beppe Calò <sup>2</sup>, Francesco Del Giudice <sup>3</sup> , Satvir Basran <sup>4</sup>, Benjamin I. Chung <sup>4</sup>, Angelo Porreca <sup>5</sup>, Lorenzo Bianchi <sup>6</sup> , Riccardo Schiavina <sup>6</sup>, Eugenio Brunocilla <sup>6</sup>, Gian Maria Busetto <sup>1,\*</sup> , Carlo Bettocchi <sup>1</sup>, Pasquale Annesi <sup>1</sup>, Luigi Cormio <sup>1,2</sup> and Giuseppe Carrieri <sup>1</sup>

<sup>1</sup> Department of Urology and Renal Transplantation, Policlinico Riuniti di Foggia, University of Foggia, 71122 Foggia, Italy

<sup>2</sup> Department of Urology, Bonomo Teaching Hospital, 76123 Andria, Italy

<sup>3</sup> Department of Urology, Sapienza Rome University, 00185 Rome, Italy

<sup>4</sup> Department of Urology, Stanford University School of Medicine, Stanford, CA 94305, USA

<sup>5</sup> Oncological Urology, Veneto Institute of Oncology (IOV), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 37138 Padua, Italy

<sup>6</sup> Department of Urology, University of Bologna, 40126 Bologna, Italy

\* Correspondence: gianmaria.busetto@unifg.it; Tel.: +39-0881-733856



**Citation:** d'Altilia, N.; Mancini, V.; Falagario, U.G.; Martino, L.; Di Nauta, M.; Calò, B.; Del Giudice, F.; Basran, S.; Chung, B.I.; Porreca, A.; et al. A Matched-Pair Analysis after Robotic and Retropubic Radical Prostatectomy: A New Definition of Continence and the Impact of Different Surgical Techniques.

*Cancers* **2022**, *14*, 4350.

<https://doi.org/10.3390/cancers14184350>

Academic Editor: Ana Faustino

Received: 8 August 2022

Accepted: 4 September 2022

Published: 7 September 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

**Simple Summary:** The primary goal of radical prostatectomy is oncologic efficacy, but mitigation of the side effects related to prostatectomy is also important to preserve quality of life in these patients. In recent decades, robotic prostatectomy has become increasingly popular due to advantages related to better visualization of the anatomical structures, surgical precision, reduced blood loss, and shorter hospital stay. However, the available literature shows no difference in oncologic outcomes between robotic and open. Some authors suggest differences in its potential to improve functional outcomes, i.e., erectile function and urinary continence. The first is certainly more common but more accepted than urinary incontinence, considering that some patients already suffer from it before surgery and others are not particularly interested in recovering from it, unlike urinary incontinence, which causes psychophysical changes that are often difficult to resolve.

**Abstract:** (1) Background: Radical prostatectomy is considered the gold-standard treatment for patients with localized prostate cancer. The literature suggests there is no difference in oncological and functional outcomes between robotic-assisted radical prostatectomy (RARP) and open (RRP). (2) Methods: The aim of this study was to compare continence recovery rates after RARP and RRP measured with 24 h pad weights and the International Consultation on Incontinence Questionnaire—Short Form (ICIQ-SF). After matching the population (1:1), 482 met the inclusion criteria, 241 patients per group. Continent patients with a 24 h pad test showing <20 g of urinary leakage were considered, despite severe incontinence, and categorized as having >200 g of urinary leakage. (3) Results: There was no difference between preoperative data. As for urinary continence (UC) and incontinence (UI) rates, RARP performed significantly better than RRP based on objective and subjective results at all evaluations. Univariable and multivariable Cox Regression Analysis pointed out that the only significant predictors of continence rates were the bilateral nerve sparing technique (1.25 (CI 1.02,1.54),  $p = 0.03$ ) and the robotic surgical approach (1.42 (CI 1.18,1.69)  $p \leq 0.001$ ). (4) Conclusions: The literature reports different incidences of UC depending on assessment and definition of continence “without pads” or “social continence” based on number of used pads per day. In this, our first evaluation, the advantage of objective measurement through the weight of the 24 h and subjective measurement with the ICIQ-SF questionnaire best demonstrates the difference between the two surgical techniques by enhancing the use of robotic surgery over traditional surgery.

**Keywords:** prostate cancer; male incontinence; robotic prostatectomy

## 1. Introduction

RP is considered the gold-standard treatment for patients with localized prostate cancer (PCa) and a life expectancy of more than 10 years [1]. The main goal of RP is oncological efficacy, but care is taken to preserve the anatomical structures surrounding the prostate to reduce the receipt of side effects, without compromising oncologic outcomes. Over the last twenty years, RARP has gained popularity and is now used on more than half of patients undergoing surgery for PCa [2]. The robotic platform allows an immersive surgical experience with magnified 3D high-definition vision and depth perception. The surgeon can see tissue planes clearly, identify structures, and dissect with a higher level of precision. This is expected to result in better oncological and functional outcomes [3].

However, the available literature suggests that there is no difference in oncological outcomes between RARP and RRP. The robotic approach has undeniably reduced blood loss and length of stay, but questions remain as to its ability to improve functional outcomes, such as erectile function and UC. Erectile dysfunction (ED) is a common side effect and those who experience ED after surgery and are motivated to regain erectile function can rely on several effective non-surgical and surgical treatments. Conversely, UI is less common but can be more psychologically challenging due to the fact that very few patients have underlying pre-RP UI. Due to this impact of de novo post-RP incontinence, all are strongly motivated to regain continence after surgery, but treatment options can often require additional surgical procedures, which can be a daunting prospect.

Prospective randomized trials comparing open and robotic surgery demonstrated comparable results in terms of early (85% vs. 84%,  $p = 0.8$ ) [4] and late (91% vs. 90%,  $p = 0.6$ ) [5] continence recovery following both techniques, whereas systematic reviews and meta-analyses showed better continence recovery at 12 months in favor of RARP (OR: 1.53,  $p = 0.03$ ) (R: 2.84,  $p = 0.002$ ) [6,7].

Therefore, due these above conflicting data, the aim of this study was to compare the continence recovery rates after RARP and RRP using pad weights over a 24 h period and to determine predictive factors for continence recovery.

## 2. Materials and Methods

### 2.1. Eligibility Criteria

The Da Vinci Xi surgical system has been available at our institution since January 2016; since then, RARP has become the preferred approach for RP, with RRP being performed only in the few patients who refuse or are not considered fit for robotic surgery due to their comorbidities.

For the present study, we queried our Internal-Review-Board-approved prospective database on PCa to identify patients that underwent RARP ( $n = 600$ ), had a minimum follow-up of 12 months, and a matched population of patients that underwent RRP ( $n = 945$ ) between January 2010 and December 2015. Patients with incomplete clinical data or those who had adjuvant treatment after surgery were excluded. Additionally, the first 100 patients who underwent RARP were excluded due to the possible impact of the learning curve on functional outcomes [8].

According to our policy [9–11], all patients had uroflowmetry with evaluation of peak flow rate (Q-max) and a post-void residual urinary volume (PVR). Transrectal ultrasound was used to measure both Pvol and to calculate PSA density.

For RRP, we used the technique described by Walsh [12], whereas for the RARP we used an intraperitoneal access and an anterograde dissection through the space of Retzius [13,14]. Pelvic lymph node dissection was carried out according to Briganti nomogram indications using an extended template as recommended by EAU guidelines [1]. The criteria for neurovascular bundle preservation were identical for both procedures and were carefully balanced against the risk of positive surgical margins [15–17]. The vesicourethral anastomosis, always preceded by posterior reconstruction [18], required 6 stitches in RRP, while RARP required 2 barbed running sutures. A drain was always placed at the end

of each procedure and all patients underwent a retrograde cystogram prior to bladder catheter removal.

UC was assessed and discussed by two dedicated “Continence Nurses” before surgery and then 7 days after catheter removal. Patients were seen weekly for the first post-operative month in a formal pelvic floor rehabilitation program and then at 3, 6, and 12 months. During all visits, the ability to perform Kegel exercises was assessed; in addition, data on 24 h pad test and ICIQ-7 questionnaire were recorded.

## 2.2. Statistical Analysis

The primary study objective was to compare the rates of patients continent at 1 week, 1 month, 6 months, and 1 year after the two procedures.

To control for measured potential confounders in the data set, a 1:1 propensity score (PS)-matched population of patients undergoing RP was selected using age at surgery, PSA, Biopsy Gleason Grade Group (GGG), and digital rectal exam (DRE). After PS matching, the quality of covariate balance was checked by assessment of standardized differences. Continuous variables were reported as median and interquartile range and compared by the Mann–Whitney U-test, whereas categorical variables were reported as rates and tested by the Fisher’s exact test or the chi-square test, as appropriate. A Kaplan–Meier curve of the probability of urinary continence recovery following RP over time was created. Finally, uni- and multivariable Cox regression analysis, involving the entire study cohort, was used to evaluate predictors of continence. Statistical analyses were performed using Stata-SE 15 (StataCorp LP, College Station, TX, USA). All tests were 2-sided with a significance level set at  $p < 0.05$ .

## 3. Results

After propensity score matching of the patient population, 482 met the inclusion criteria, 241 patients per group; Table 1 shows the preoperative characteristics of the study population. Of note, there were no differences in age, DRE, PSA, preoperative IIEF-5 score, IPSS, maximum peak flow rate (Q-max), PVR, Pvol, and biopsy GGG.

**Table 1.** Preoperative characteristics of the study population after propensity matching.

Characteristics	RRP <sup>1</sup> n = 241 (50%)	RARP <sup>1</sup> n = 241 (50%)	p-Value <sup>2</sup>
Age at surgery (y)	66.0 (62.0, 71.0)	66.0 (61.0, 70.0)	0.2
PSA, (ng/mL)	6.2 (4.6, 9.1)	6.2 (4.8, 9.2)	0.6
DRE, n (%)			
Negative	125 (52%)	119 (49%)	0.6
Positive	116 (48%)	122 (51%)	
Biopsy GGG, n (%)			
1	110 (46%)	110 (46%)	0.9
2	57 (24%)	64 (27%)	
3	42 (17%)	41 (17%)	
4	22 (9%)	19 (8%)	
5	10 (4%)	7 (3%)	
Prostate volume (cm <sup>3</sup> )	40.0 (31.0, 56.0)	40.0 (32.0, 55.0)	1
Q-max (mL/s)	15.6 (12.0, 18.6)	14.0 (11.7, 21.0)	0.7
PVR (mL)	20.0 (1.0, 40.0)	30.0 (1.0, 50.0)	0.060
Pre-operative IPSS	7.0 (4.0, 12.0)	7.0 (3.0, 12.0)	0.3
Pre-operative IIEF	19.0 (11.0, 22.0)	20.0 (15.0, 23.0)	0.067
Nerve Sparing			
Non nerve sparing	172 (71.4%)	141 (58.5%)	0.002
Unilateral	26 (10.8%)	23 (9.5%)	
Bilateral	43 (17.8%)	77 (32.0%)	

<sup>1</sup> Median (IQR); n (%). <sup>2</sup> Wilcoxon rank-sum test, Pearson’s Chi-square test.

As for UC rates (Table 2), RARP performed significantly better than RRP at all time points. The continence rate for RARP and RRP was 58% vs. 47% at 1 week ( $p = 0.018$ ), 82% vs. 61% at 1 month ( $p < 0.0001$ ), 92% vs. 75% at 6 months ( $p < 0.0001$ ), and 94% vs. 80% at 1 year ( $p < 0.0001$ ), respectively.

**Table 2.** Continence recovery rates (pad 0–20 gr) in patients undergoing RRP and RARP at 1 week, 1 month, 6 month, and 1-year follow-up.

Characteristic	RRP <sup>1</sup> n = 241 (50%)	RARP <sup>1</sup> n = 241 (50%)	p-Value <sup>2</sup>
<b>1 week</b>			
Pad < 20 gr, n (%)	114 (47%)	140 (58%)	0.018
ICIQ score *	9.0 (5.0, 13.0)	7.0 (4.0, 10.0)	0.011
<b>1 month</b>			
Pad < 20 gr, n (%)	148 (61%)	198 (82%)	<0.0001
ICIQ score *	8 (5, 21)	7 (0, 21.0)	0.001
<b>6 months</b>			
Pad < 20 gr, n (%)	180 (75%)	222 (92%)	<0.0001
ICIQ score *	5 (0, 10)	4 (0, 6)	0.029
<b>1 year</b>			
Pad < 20 gr, n (%)	193 (80%)	227 (94%)	<0.0001
ICIQ score *	5 (0, 8)	3 (0, 6)	0.09

<sup>1</sup> Median (IQR); n (%). <sup>2</sup> Wilcoxon rank-sum test, Pearson's Chi-square test. \* ICIQ: International Consultation Incontinence Questionnaire—short form (ICIQ-short form).


Further, RARP performed significantly better than RRP in UI (Table 3), since severe leakage (>200 gr/24 h) was 40.9% vs. 15.8% at 6 months ( $p = 0.04$ ) and 39.6% vs. 7.1% at 1 year ( $p = 0.02$ ), in favor of RARP. Furthermore, Table 3 shows the trends in the score on the ICIQ questionnaire, which reflects the trend in the overall severity of urinary incontinence.

**Table 3.** Incontinence recovery rates (pad > 20 gr) in patients undergoing RRP and RARP at 1 week, 1 month, 6 month, and 1-year follow-up.

Characteristic	RRP <sup>1</sup> n = 241 (50%)	RARP <sup>1</sup> n = 241 (50%)	p-Value <sup>2</sup>
<b>1 Week</b>			
21–200 gr, n (%)	63 (49.6%)	82 (81.2%)	0.00001
ICIQ score *	20.5 (18, 21)	20.5 (18, 21)	0.27
>200 gr, n (%)	64 (50.4%)	19 (18.8%)	0.00001
ICIQ score *	21 (21, 21)	21 (21, 21)	0.72
<b>1 Month</b>			
21–100 gr, n (%)	44 (47.3%)	35 (81.4%)	0.00001
ICIQ score *	15 (9, 21)	10 (7, 15)	0.27
>200 gr, n (%)	51 (54.8%)	8 (18.6%)	0.00001
ICIQ score *	21 (21, 21)	21 (21, 21)	0.4
<b>6 Month</b>			
21–100 gr, n (%)	36 (59.1%)	16 (84.2%)	0.04
ICIQ score *	10 (7, 17)	10 (6, 16)	0.52
>200 gr, n (%)	25 (40.9%)	3 (15.8%)	0.04
ICIQ score *	21 (18, 21)	15 (10, 16)	0.58
<b>1 Year</b>			
21–100 gr, n (%)	29 (60.4%)	13 (82.9%)	0.02
ICIQ score *	10 (8, 15)	10 (7, 10)	0.51
>200 gr, n (%)	19 (39.6%)	1 (7.1%)	0.02
ICIQ score *	21 (21, 21)	21 (21, 21)	0.52

<sup>1</sup> Median (IQR); n (%). <sup>2</sup> Wilcoxon rank-sum test, Pearson's Chi-square test. \* ICIQ: International Consultation Incontinence Questionnaire - short form (ICIQ-short form).

Kaplan–Maier curves (Figure 1) confirmed a significant difference in continence rates between techniques (Figure 1a), especially in those who received a bilateral nerve sparing (Figure 1b).



**Figure 1.** Continence recovery rates between RRP and RALP at follow-up after propensity matching,  $Pr > \chi^2 \leq 0.0001$  (a). Continence recovery rates divided by nerve sparing grade on the entire population study,  $Pr > \chi^2 = 0.0012$  (b).

In Table 4, the analysis on the entire study population (n = 482 patients) identified the bilateral nerve-sparing technique and robotic surgical approach as having significant predictor value of continence rates (1.25 (CI 1.02,1.54),  $p = 0.030$ ; 1.42 (CI 1.18,1.69),  $p \leq 0.001$ ).

**Table 4.** Univariable and multivariable Cox Regression Analysis to predict continence recovery in the entire population.

Covariate	Univariable Cox Regression Analysis			Multivariable Cox Regression Analysis		
	Haz. Ratio	95% CI	p Value	Haz. Ratio	95% CI	p Value
<b>Age</b>	0.99	0.98, 1.00	0.174			
<b>GGG biopsy</b>						
1	Ref.			Ref.		
2	1.05	0.84, 1.31	0.661	1.02	0.82, 1.28	0.857
3	0.87	0.67, 1.13	0.301	0.90	0.69, 1.17	0.430
4	0.88	0.68, 1.14	0.329	0.98	0.75, 1.28	0.876
5	1.03	0.72, 1.47	0.877	1.15	0.80, 1.65	0.462
<b>Prostate volume</b>						
Q-max	1.00	0.99, 1.00	0.231			
PVR	1.00	1.00, 1.01	0.464			
IPSS	0.99	0.97, 1.00	0.155			
IIEF	1.01	1.00, 1.02	0.163			
<b>Nerve sparing</b>						
No	Ref.			Ref.		
Unilateral	1.06	0.79, 1.43	0.711	1.01	0.75, 1.37	0.932
Bilateral	1.35	1.10, 1.64	0.003	1.25	1.02, 1.54	0.030
<b>Catheters days</b>						
≥8	Ref.					
<8	0.85	0.72, 1.00	0.056	0.88	0.75, 1.05	0.159

Table 4. Cont.

Covariate	Univariable Cox Regression Analysis			Multivariable Cox Regression Analysis		
	Haz. Ratio	95% CI	<i>p</i> Value	Haz. Ratio	95% CI	<i>p</i> Value
Surgery type						
RRP	Ref.			Ref.		
RARP	1.46	1.23, 1.73	<0.001	1.42	1.18, 1.69	<0.001

#### 4. Discussion

This study demonstrates better early and late recovery continence and lower rates of UI favoring RARP. Further, we show an overall benefit of the bilateral nerve-sparing approach as a factor in facilitating urinary recovery. Further, regarding time to continence, our data showed not only better but also faster continence recovery with RARP than with RRP. Indeed, RARP performed better than RRP at all evaluation times, considering continence rates were 47% vs. 58% at 1 week ( $p = 0.018$ ), 61% vs. 82% at 1 month ( $p = 0.001$ ), 75% vs. 92% at 6 months ( $p = 0.018$ ), and 80% vs. 94% at 1 year ( $p = 0.001$ ).

UC rates after open and robotic prostatectomy vary widely in the available literature and several factors may explain these differences. The robotic approach has clear advantages, including better visualization of delicate structures involved in continence recovery [14–20] and higher surgical precision in the reconstructive phase. However, on the flip side, in reported series, up to 31% might have UI (pad > 0) at 1 year [7]. Patient and cancer characteristics, operative techniques, surgical experience, surgeon dexterity, high-volume centers, post-operative urinary rehabilitation, and adjuvant treatments are all factors to be consider when comparing post-prostatectomy results [21,22]. In this setting, the only existing randomized prospective study showed similar and comparable results in oncological and functional aspects, both in the short and long term [4–7,21,22], although the functional domain was judged on data acquired from questionnaires administered at follow-up and with no mention of postoperative rehabilitation.

The level of evidence of most of the published data is retrospective and, by nature, limited by selection bias. Furthermore, in the first ten years after the introduction of robotic technology, many studies were characterized by a significant publication bias, with post-RARP continence rates (pad 0) reported up to 50–80%, 90–96%, and 89% to 98%, interesting values after catheter removal compared with open at 6 and 12 months, respectively [23]. Further, Patel et al. [24] reported his technique of RARP provided a 1-year continence rate (pad 0) of 96.4% and Menon et al., a 6-month continence rate (pads  $\leq 1$ ) of 92% [13].

Subsequent data have been conflicting in nature regarding any advantages in continence with the robotic approach. An early meta-analysis compared the two techniques in terms of recovery of UC at 12 months and showed significant advantages to a robotic approach (OR: 1.53; 95% CI, 1.04–2.25;  $p = 0.03$ ). Indeed, after RARP, continence recovery ranged from 89% to 100% compared to RRP, which ranges from 80% to 97% [7,25–27]. However, this new technology still exposed patients to IU, though with less impact (11% vs. 7%). Similarly, Seo et al. compared 10 matching studies between open and robotic RP with 2214 patients and reported a lower incontinence rate after RARP (RR 0.66, 95% CI 0.45–0.99, I<sup>2</sup> = 45%;  $p = 0.040$ ) [28].

Subsequently, several authors began to present data that demonstrated minimal differences in continence between the open and robotic approaches. A 2017 meta-analysis included 78 studies, in which Kun Tang showed no statistical differences in the 3-month and 12-month UC within the two surgical techniques (3 months: OR:1.54; 95% CI: 0.92 to 2.58;  $p = 0.10$ ; 12 months: OR:1.03; 95% CI: 0.84 to 1.27;  $p = 0.75$ , respectively) [29]. Similarly, Lan Cao et al. published a systematic review and meta-analysis in 2019 with 8522 patients and found no difference in the 12-month continence rates among the two procedures. UC was defined as either no pad use or no leakage (71.6% vs. 70.8%; OR 1.14, 95% CI 0.99 to 1.31,  $p = 0.08$ ) [30]. In a 1:2 matching population series between 294 and 588 patients undergoing RARP and RRP, one-year continence recovery rate (security pad) was overlapping

(93.7% vs. 91.8%;  $p = 0.34$ ) also [31]. Several meta-analyses pointed out that the data were insufficient to define a technique as superior, given variables related to surgeon experience, patient history, and oncologic finding.

Quantifying the degree and severity of urinary incontinence has been an area of ongoing debate. Even though pad weight and pad usage are well correlated with quality of life [32], the variability in the definitions used in the literature makes it difficult to objectify an outcome and, therefore, make a real comparison among the results of traditional and technological surgery. The above-mentioned studies in recent years have only assessed incontinence by interviewing the patient based on the number of pads used per day (0, 0–1, one safety pad). Therefore, the differences between the two techniques are not highlighted, emphasizing the use of technology but not for functional advantages.

The rate of functional recovery also varies widely in proportion to pad use. As a result, one study pointed out that the continence rate after RP at 3 and 12 months was 44% and 68% when defined as “pad 0” and increased to 71% and 90% when defined as “pad 0–1” [33]. In addition, a systematic review, reported average values of post-RARP incontinence at 1 year of 16% and 9% according to the definition of “dry” or “a safe pad” [7]. Although Holze et al. argues zero pads best reflects the perception of “dry” [33], Moore et al., suggests a minimum value greater than 4 g/day of leakage as incontinence after prostatectomy, but greater than 20 g/day is characterized as symptomatic incontinence [34]. We, therefore, chose the threshold of a 24 h pad weight test greater than 20 g as a reasonable value for assessing symptomatic male incontinence after an RP. However, a 0 g pad in 24 h is not easy to obtain, as sweat can also increase the weight of the pad and can classify a continent patient as incontinent. For this reason, other definitions are established, such as socially continent. With this, 20 g as a threshold seems reasonable and easy to assess to define a patient as socially continent.

Based on our experience, we have historically chosen to avoid testing UC through interviews about pad count, which is strongly related to subjective feelings of “wetness”. Instead, we choose “third-party” assessment by a urinary specialist nurse who objectively records the 24 h pad weight test at follow-up. We believe it is a reliable tool for assessing the presence and degree of urinary leakage and combining it with those obtained from the recognized ICIQ-7 subjective questionnaire for UI [35].

Others have used 24 h pad weight as an objective measurement of the degree of incontinence. In 2010, Dubbelman was the first to present functional outcomes after RRP using the 24 h pad weight test at 6 months in a series of 66 patients. He reported recovery of continence, defined as 4 g per day, in 44% of patients who were receiving a “Continence Nurses” or folder-guided approach [36]. In 2017, Sathianathen was the first to present functional outcomes after RARP using 24 h pad weight test. Using zero grams as a definition, Sathianathen reported continence recovery after RARP in 20% and 38% of patients, respectively, after 4 and 12 weeks, with average continence recovery at 10 weeks. They also pointed out the fact that if the number of pads had been used as the definition, it would probably have produced better results than UC [37].

However, currently, the 24 h pad test is used by less than 1 out of 10 clinicians [38]. It is considered a controversial way of objectively reporting a measure of male post-prostatectomy UI [39], because the weight of the 24 h pad is directly influenced by daily activity and fluid intake and the same weight can vary by 51 g (95% CI 30.3–72.1,  $p < 0.001$ ) in those who do not change their activity level. On the other hand, what is perceived to be a single wet pad can range from 23 to 121 g and it is these values that make an objective comparison of the degree of leakage possible. More importantly, for each 1-unit increase in pads used, the average pad weight increased by 114.1 g (95% CI 74.8–153.4,  $p < 0.001$ ) [40]. With this in mind, the definition of “Pad 0–1” may not reflect continence status as it may include symptomatic urinary leakage [34]. The added value of our study is to better stratify patients and define already symptomatic incontinent patients with >20 g or more of leakage who, in other definitions, would be continent.

Additional studies suggest that characteristics, such as age, body mass index (BMI), Pvol, and lower urinary tract disorders (LUTS), influence functional outcomes [40–42]. As we have previously shown, age did not influence continence recovery in RRP [43], even though Jeong found advantages in young patients, both in early and long-term follow-up [44] and Becker claims that beyond the age of 50, the recovery rate drops from 97.4% to 91.6% [45].

Another interesting insight of the analysis suggests that bilateral sparing of the neurovascular bundles is advantageous in facilitating recovery of UC on an entire study population, especially in RARP, as shown in multivariate analysis (Table 4) and Kaplan–Meier curves (Figure 1b). In this context, the benefits of nerve sparing on continence recovery, both in the short term and long term for RRP and RARP, have already been reported [46–48]. These findings are so strong that Steineck continues to recommend nerve sparing, regardless of age and preoperative erectile function, as the benefits are significant [49].

One of the strengths of our study was the management and evaluation of the prostatectomized matching pair population that was entrusted to the “urinary nurse” who trained and collected the data ensuring an unbiased evaluation. The definition was based on the objective measurement of a 24 h pad test in grams rather than on the pad use together with the subjective data obtained from the ICIQ-SF questionnaire. Having stated that, the results obtained justify the use of robotic surgery, not only for less blood loss and hospitalization but also for its impact on the recovery of UC and quality of life.

This work certainly has limitations; first, this is a retrospective analysis of prospectively collected data. Further, body mass index (BMI) and an assessment of preoperative continence were not assessed. However, in the second case, we have a subjective comparison of LUTS through the IPSS questionnaire with overlapping results between the two groups.

## 5. Conclusions

In urologic oncologic surgery, to date, robotic surgery has brought advantages in terms of decreases in blood loss, shorter hospitalization, and, possibly, improved quality of life. When it comes to treating localized prostate cancer, a prostatectomy not only has oncologic but also functional implications. In terms of continence recovery, our study demonstrates that, with a rigorous objective evaluation of postoperative urinary leakage, robotic prostatectomy has advantages over traditional surgery, in both short- and long-term measures of continence.

**Author Contributions:** Conceptualization, N.d., V.M., L.C. and U.G.F.; Data curation, N.d., G.M.B., L.M., M.D.N. and B.C.; Formal analysis, U.G.F., L.M., L.C. and V.M.; Investigation, N.d., V.M., G.M.B., L.B., L.C., G.C., C.B., P.A. and B.C.; Methodology, N.d., G.M.B., L.M., M.D.N., L.C., G.C. and C.B.; Project administration, N.d., G.M.B., L.M., M.D.N., L.C., G.C. and C.B.; Resources, F.D.G., S.B. and L.M.; Software, U.G.F., F.D.G. and S.B.; Supervision, G.C., L.C., E.B. and R.S.; Validation, C.B., F.D.G., S.B., L.B., L.C., G.C., C.B., P.A. and G.M.B.; Visualization, F.D.G., S.B. and C.B.; Writing—original draft, N.d.; Writing—review and editing, N.d., V.M., G.M.B., L.B., L.C., G.C., C.B., P.A., A.P. and B.I.C. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Department of Urology and Renal Transplantation, Policlinico Riuniti di Foggia, University of Foggia Department of Urology, University of Foggia, approval code: 143/CE/2020 and approved on DDG n.696 01.12.2020.

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author. The data are not publicly available.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Mottet, N.; van den Bergh, R.C.N.; Briers, E.; Van den Broeck, T.; Cumberbatch, M.G.; De Santis, M.; Fanti, S.; Fossati, N.; Gandaglia, G.; Gillessen, S.; et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. *Eur. Urol.* **2021**, *79*, 243–262. [[CrossRef](#)] [[PubMed](#)]
2. Mottrie, A.; Larcher, A.; Patel, V. The Past, the Present, and the Future of Robotic Urology: Robot-assisted Surgery and Human-assisted Robots. *Eur. Urol. Focus* **2018**, *4*, 629–631. [[CrossRef](#)] [[PubMed](#)]
3. Leal Ghezzi, T.; Campos Corleta, O. 30 Years of Robotic Surgery. *World J. Surg.* **2016**, *40*, 2550–2557. [[CrossRef](#)] [[PubMed](#)]
4. Yaxley, J.W.; Coughlin, G.D.; Chambers, S.K.; Occhipinti, S.; Samaratunga, H.; Zajdlewicz, L.; Dunglison, N.; Carter, R.; Williams, S.; Payton, D.J.; et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: Early outcomes from a randomised controlled phase 3 study. *Lancet* **2016**, *388*, 1057–1066. [[CrossRef](#)]
5. Coughlin, G.D.; Yaxley, J.W.; Chambers, S.K.; Occhipinti, S.; Samaratunga, H.; Zajdlewicz, L.; Teloken, P.; Dunglison, N.; Williams, S.; Lavin, M.F.; et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study. *Lancet Oncol.* **2018**, *19*, 1051–1060. [[CrossRef](#)]
6. Ficarra, V.; Novara, G.; Ahlering, T.E.; Costello, A.; Eastham, J.A.; Graefen, M.; Guazzoni, G.; Menon, M.; Mottrie, A.; Patel, V.R.; et al. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. *Eur. Urol.* **2012**, *62*, 418–430. [[CrossRef](#)]
7. Ficarra, V.; Novara, G.; Rosen, R.C.; Artibani, W.; Carroll, P.R.; Costello, A.; Menon, M.; Montorsi, F.; Patel, V.R.; Stolzenburg, J.U.; et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. *Eur. Urol.* **2012**, *62*, 405–417. [[CrossRef](#)]
8. Ou, Y.C.; Yang, C.K.; Chang, K.S.; Wang, J.; Hung, S.W.; Tung, M.C.; Tewari, A.K.; Patel, V.R. The surgical learning curve for robotic-assisted laparoscopic radical prostatectomy: Experience of a single surgeon with 500 cases in Taiwan, China. *Asian J. Androl.* **2014**, *16*, 728–734. [[CrossRef](#)]
9. Cormio, L.; Lucarelli, G.; Selvaggio, O.; Di Fino, G.; Mancini, V.; Massenio, P.; Troiano, F.; Sanguedolce, F.; Bufo, P.; Carrieri, G. Absence of Bladder Outlet Obstruction Is an Independent Risk Factor for Prostate Cancer in Men Undergoing Prostate Biopsy. *Medicine* **2016**, *95*, e2551. [[CrossRef](#)]
10. Cormio, L.; Lucarelli, G.; Netti, G.S.; Stallone, G.; Selvaggio, O.; Troiano, F.; Di Fino, G.; Sanguedolce, F.; Bufo, P.; Grandaliano, G.; et al. Post-void residual urinary volume is an independent predictor of biopsy results in men at risk for prostate cancer. *Anticancer Res.* **2015**, *35*, 2175–2182.
11. Cormio, L.; Cindolo, L.; Troiano, F.; Marchioni, M.; Di Fino, G.; Mancini, V.; Falagario, U.; Selvaggio, O.; Sanguedolce, F.; Fortunato, F.; et al. Development and Internal Validation of Novel Nomograms Based on Benign Prostatic Obstruction-Related Parameters to Predict the Risk of Prostate Cancer at First Prostate Biopsy. *Front. Oncol.* **2018**, *16*, 438. [[CrossRef](#)] [[PubMed](#)]
12. Walsh, P.C. Anatomic radical prostatectomy: Evolution of the surgical technique. *J. Urol.* **1998**, *160 Pt 2*, 2418–2424. [[CrossRef](#)]
13. Menon, M.; Tewari, A.; Peabody, J.; VIP Team. Vattikuti Institute prostatectomy: Technique. *J. Urol.* **2003**, *169*, 2289–2292. [[CrossRef](#)]
14. Martini, A.; Falagario, U.G.; Villers, A.; Dell’Oglio, P.; Mazzone, E.; Autorino, R.; Moschovas, M.C.; Buscarini, M.; Bravi, C.A.; Briganti, A.; et al. Contemporary Techniques of Prostate Dissection for Robot-assisted Prostatectomy. *Eur. Urol.* **2020**, *78*, 583–591. [[CrossRef](#)] [[PubMed](#)]
15. Falagario, U.G.; Jambor, I.; Ratnani, P.; Martini, A.; Treacy, P.J.; Wajswol, E.; Lantz, A.; Papastefanou, G.; Weil, R.; Phillip, D.; et al. Performance of prostate multiparametric MRI for prediction of prostate cancer extra-prostatic extension according to NCCN risk categories: Implication for surgical planning. *Minerva Urol. Nefrol.* **2020**, *72*, 746–754. [[CrossRef](#)] [[PubMed](#)]
16. Martini, A.; Kumarasamy, S.; Gupta, A.; Falagario, U.G.; Shah, Q.N.; Beksac, A.T.; Haines, K.G.; Tewari, A.K. Clinical implications of prostatic capsular abutment or bulging on multiparametric magnetic resonance imaging. *Minerva Urol. Nefrol.* **2019**, *71*, 502–507. [[CrossRef](#)]
17. Martini, A.; Marqueen, K.E.; Falagario, U.G.; Waingankar, N.; Wajswol, E.; Khan, F.; Fossati, N.; Briganti, A.; Montorsi, F.; Tewari, A.K.; et al. Estimated Costs Associated with Radiation Therapy for Positive Surgical Margins During Radical Prostatectomy. *JAMA Netw. Open* **2020**, *3*, e201913. [[CrossRef](#)]
18. Rocco, B.; Gregori, A.; Stener, S.; Santoro, L.; Bozzola, A.; Galli, S.; Knez, R.; Scieri, F.; Scaburri, A.; Gaboardi, F. Posterior reconstruction of the rhabdosphincter allows a rapid recovery of continence after transperitoneal videolaparoscopic radical prostatectomy. *Eur. Urol.* **2007**, *51*, 996–1003. [[CrossRef](#)]
19. Sheetz, K.H.; Clafin, J.; Dimick, J.B. Trends in the Adoption of Robotic Surgery for Common Surgical Procedures. *JAMA Netw. Open* **2020**, *3*, e1918911. [[CrossRef](#)]
20. Haglund, E.; Carlsson, S.; Stranne, J.; Wallerstedt, A.; Wilderäng, U.; Thorsteinsdottir, T.; Lagerkvist, M.; Damber, J.E.; Bjartell, A.; Hugosson, J.; et al. Urinary Incontinence and Erectile Dysfunction after Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial. *Eur. Urol.* **2015**, *68*, 216–225. [[CrossRef](#)]
21. Kim, S.C.; Song, C.; Kim, W.; Kang, T.; Park, J.; Jeong, I.G.; Lee, S.; Cho, Y.M.; Ahn, H. Factors determining functional outcomes after radical prostatectomy: Robot-assisted versus retropubic. *Eur. Urol.* **2011**, *60*, 413–419. [[CrossRef](#)] [[PubMed](#)]

22. Trieu, D.; Ju, I.E.; Chang, S.B.; Mungovan, S.F.; Patel, M.I. Surgeon case volume and continence recovery following radical prostatectomy: A systematic review. *ANZ J. Surg.* **2021**, *91*, 521–529. [[CrossRef](#)] [[PubMed](#)]
23. Singh, I.; Hemal, A.K. Robotic-assisted radical prostatectomy in 2010. *Expert Rev. Anticancer Ther.* **2010**, *10*, 671–682. [[CrossRef](#)] [[PubMed](#)]
24. Patel, V.R.; Sivaraman, A.; Coelho, R.F.; Chauhan, S.; Palmer, K.J.; Orvieto, M.A.; Camacho, I.; Coughlin, G.; Rocco, B. Pentafecta: A new concept for reporting outcomes of robot-assisted laparoscopic radical prostatectomy. *Eur. Urol.* **2011**, *59*, 702–707. [[CrossRef](#)]
25. Ficarra, V.; Novara, G.; Fracalanza, S.; D’Elia, C.; Secco, S.; Iafrate, M.; Cavalleri, S.; Artibani, W. A prospective, non-randomized trial comparing robot-assisted laparoscopic and retropubic radical prostatectomy in one European institution. *BJU Int.* **2009**, *104*, 534–539. [[CrossRef](#)]
26. Di Pierro, G.B.; Baumeister, P.; Stucki, P.; Beatrice, J.; Danuser, H.; Mattei, A. A prospective trial comparing consecutive series of open retropubic and robot-assisted laparoscopic radical prostatectomy in a centre with a limited caseload. *Eur. Urol.* **2011**, *59*, 1–6. [[CrossRef](#)]
27. Ou, Y.C.; Yang, C.R.; Wang, J.; Cheng, C.L.; Patel, V.R. Comparison of robotic-assisted versus retropubic radical prostatectomy performed by a single surgeon. *Anticancer Res.* **2009**, *29*, 1637–1642. [[CrossRef](#)]
28. Seo, H.-J.; Lee, N.R.; Son, S.K.; Kim, D.K.; Rha, K.H.; Lee, S.H. Comparison of Robot-Assisted Radical Prostatectomy and Open Radical Prostatectomy Outcomes: A Systematic Review and Meta-Analysis. *Yonsei Med. J.* **2016**, *57*, 1165–1177. [[CrossRef](#)]
29. Tang, K.; Jiang, K.; Chen, H.; Chen, Z.; Xu, H.; Ye, Z. Robotic vs. Retropubic radical prostatectomy in prostate cancer: A systematic review and a meta-analysis update. *Oncotarget* **2017**, *8*, 32237–32257. [[CrossRef](#)]
30. Cao, L.; Yang, Z.; Qi, L.; Chen, M. Robot-assisted and laparoscopic vs open radical prostatectomy in clinically localized prostate cancer: Perioperative, functional, and oncological outcomes: A Systematic review and meta-analysis. *Medicine* **2019**, *98*, e15770. [[CrossRef](#)]
31. Krambeck, A.E.; DiMarco, D.S.; Rangel, L.J.; Bergstralh, E.J.; Myers, R.P.; Blute, M.L.; Gettman, M.T. Radical prostatectomy for prostatic adenocarcinoma: A matched comparison of open retropubic and robot-assisted techniques. *BJU Int.* **2009**, *103*, 448–453. [[CrossRef](#)]
32. Nitti, V.W.; Mourtzinis, A.; Brucker, B.M.; SUFU Pad Test Study Group. Correlation of patient perception of pad use with objective degree of incontinence measured by pad test in men with post-prostatectomy incontinence: The SUFU Pad Test Study. *J. Urol.* **2014**, *192*, 836–842. [[CrossRef](#)] [[PubMed](#)]
33. Holze, S.; Mende, M.; Healy, K.V.; Koehler, N.; Gansera, L.; Truss, M.C.; Rebmann, U.; Degener, S.; Stolzenburg, J.U. Comparison of various continence definitions in a large group of patients undergoing radical prostatectomy: A multicentre, prospective study. *BMC Urol.* **2019**, *19*, 70. [[CrossRef](#)] [[PubMed](#)]
34. Moore, K.N.; Truong, V.; Estey, E.; Voaklander, D.C. Urinary incontinence after radical prostatectomy: Can men at risk be identified preoperatively? *J. Wound Ostomy Cont. Nurs.* **2007**, *34*, 270–279. [[CrossRef](#)] [[PubMed](#)]
35. Karantanis, E.; Fynes, M.; Moore, K.H.; Stanton, S.L. Comparison of the ICIQ-SF and 24-hour pad test with other measures for evaluating the severity of urodynamic stress incontinence. *Int. Urogynecol. J. Pelvic Floor Dysfunct.* **2004**, *15*, 111–116. [[CrossRef](#)]
36. Dubbelman, Y.; Groen, J.; Wildhagen, M.; Rikken, B.; Bosch, R. The recovery of urinary continence after radical retropubic prostatectomy: A randomized trial comparing the effect of physiotherapist-guided pelvic floor muscle exercises with guidance by an instruction folder only. *BJU Int.* **2010**, *106*, 515–522. [[CrossRef](#)]
37. Sathianathan, N.J.; Johnson, L.; Bolton, D.; Lawrentschuk, N.L. An objective measurement of urinary continence recovery with pelvic floor physiotherapy following robotic assisted radical prostatectomy. *Transl. Androl. Urol.* **2017**, *6* (Suppl. S2), S59–S63. [[CrossRef](#)]
38. Zimmern, P.; Kobashi, K.; Lemack, G. Outcome measure for stress urinary incontinence treatment (OMIT): Results of two society of urodynamics and female urology (SUFU) surveys. *Neurourol. Urodyn.* **2010**, *29*, 715–718. [[CrossRef](#)]
39. Rasmussen, A.; Mouritsen, L.; Dalgaard, A.; Frimodt-Møller, C. Twenty-four hour pad weighing test: Reproducibility and dependency of activity level and fluid intake. *Neurourol. Urodyn.* **1994**, *13*, 261–265. [[CrossRef](#)]
40. Malik, R.D.; Cohn, J.A.; Fedunok, P.A.; Chung, D.E.; Bales, G.T. Assessing variability of the 24-hour pad weight test in men with post-prostatectomy incontinence. *Int. Braz. J. Urol.* **2016**, *42*, 327–333. [[CrossRef](#)]
41. Novara, G.; Ficarra, V.; D’elia, C.; Secco, S.; Cioffi, A.; Cavalleri, S.; Artibani, W. Evaluating urinary continence and preoperative predictors of urinary continence after robot assisted laparoscopic radical prostatectomy. *J. Urol.* **2010**, *184*, 1028–1033. [[CrossRef](#)] [[PubMed](#)]
42. Shikanov, S.; Desai, V.; Razmaria, A.; Zagaja, G.P.; Shalhav, A.L. Robotic radical prostatectomy for elderly patients: Probability of achieving continence and potency 1 year after surgery. *J. Urol.* **2010**, *183*, 1803–1807. [[CrossRef](#)] [[PubMed](#)]
43. d’Altília, N.; Di Nauta, M.; Falagario, U.G.; Calò, B.; Selvaggio, O.; Sanguedolce, F.; Mancini, V.; Stallone, G.; Barret, E.; Cormio, L.; et al. Elderly patients are not at higher risk of urinary incontinence after radical prostatectomy. *JGG* **2018**, *66*, 168–172.
44. Jeong, S.J.; Yeon, J.S.; Lee, J.K.; Cha, W.H.; Jeong, J.W.; Lee, B.K.; Lee, S.C.; Jeong, C.W.; Kim, J.H.; Hong, S.K.; et al. Development and validation of nomograms to predict the recovery of urinary continence after radical prostatectomy: Comparisons between immediate, early, and late continence. *World J. Urol.* **2014**, *32*, 437–444. [[CrossRef](#)]
45. Becker, A.; Tennstedt, P.; Hansen, J.; Trinh, Q.D.; Kluth, L.; Atassi, N.; Schlomm, T.; Salomon, G.; Haese, A.; Budaeus, L.; et al. Functional and oncological outcomes of patients aged <50 years treated with radical prostatectomy for localised prostate cancer in a European population. *BJU Int.* **2014**, *114*, 38–45. [[CrossRef](#)]

46. Michl, U.; Tennstedt, P.; Feldmeier, L.; Mandel, P.; Oh, S.J.; Ahyai, S.; Budäus, L.; Chun, F.K.H.; Haese, A.; Heinzer, H.; et al. Nerve-sparing Surgery Technique, Not the Preservation of the Neurovascular Bundles, Leads to Improved Long-term Continence Rates After Radical Prostatectomy. *Eur. Urol.* **2016**, *69*, 584–589. [[CrossRef](#)]
47. Salazar, A.; Regis, L.; Planas, J.; Celma, A.; Díaz, F.; Gallardo, I.; Trilla, E.; Morote, J. Early continence after radical prostatectomy: A systematic review. *Actas Urol. Esp.* **2019**, *43*, 526–535. [[CrossRef](#)]
48. Reeves, F.; Preece, P.; Kapoor, J.; Everaerts, W.; Murphy, D.G.; Corcoran, N.M.; Costello, A.J. Preservation of the neurovascular bundles is associated with improved time to continence after radical prostatectomy but not long-term continence rates: Results of a systematic review and meta-analysis. *Eur. Urol.* **2015**, *68*, 692–704. [[CrossRef](#)]
49. Steineck, G.; Bjartell, A.; Hugosson, J.; Axén, E.; Carlsson, S.; Stranne, J.; Wallerstedt, A.; Persson, J.; Wilderäng, U.; Thorsteinsdottir, T.; et al. Degree of preservation of the neurovascular bundles during radical prostatectomy and urinary continence 1 year after surgery. *Eur. Urol.* **2015**, *67*, 559–568. [[CrossRef](#)]